https://www.selleckchem.com/pr....oducts/aprotinin.htm
004). SES-CD was 10 (7-14) and 11 (IQR7-14), and 7 (4-14) and 8 (IQR 4-12;p=0.75)before and after treatment, in the cannabis and placebo groups, respectively. Inflammatory markers (CRP, calprotectin) remained unchanged. Eight weeks of CBD-rich cannabis treatment induced significant clinical and QOL improvement without significant changes in inflammatory parameters or endoscopic scores. The oral CBD-rich cannabis extract was well absorbed. Until further studies are available, cannabis treatment in Crohn's disease should be used only in
Like
Comment
Share
